Hospital Miguel Servet -ko ikertzaileekin lankidetzan egindako argitalpenak (14)

2022

  1. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

    European Journal of Cancer, Vol. 174, pp. 243-250

2015

  1. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution

    Leukemia

2013

  1. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

    New England Journal of Medicine, Vol. 369, Núm. 5, pp. 438-447

  2. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

2012

  1. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: Are they present at diagnosis or are they induced by lenalidomide?

    Haematologica, Vol. 97, Núm. 10, pp. 1608-1611

  2. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

    Leukemia, Vol. 26, Núm. 12, pp. 2521-2529

2010

  1. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

    Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458

2009

  1. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

    Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709

  2. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

    Blood, Vol. 114, Núm. 1, pp. 148-152

2008

  1. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia

    Haematologica, Vol. 93, Núm. 12, pp. 1797-1805

2006

  1. Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders: Biclonality versus intraclonal evolution of a single tumor cell clone

    Haematologica, Vol. 91, Núm. 3, pp. 331-339

2005

  1. Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: Impact on the clinical, biological and immunophenotypical disease characteristics

    Leukemia, Vol. 19, Núm. 5, pp. 713-720

2003

  1. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: Incidence and underlying genetic abnormalities

    Leukemia, Vol. 17, Núm. 6, pp. 1124-1129

1991

  1. Alpha interferon in the management of essential thrombocythaemia

    European Journal of Cancer and Clinical Oncology, Vol. 27, Núm. SUPPL. 4